- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT06459648
항-CGRP 항체 치료에 대한 반응 예측을 통한 만성편두통 예방을 위한 연구 (PREDI-CGRP)
편두통에 대한 항-CGRP 단클론 항체 치료에 대한 예측 연구 또는 반응
Being able to predict each patients response to a specific treatment can mean a significant improvement in socioeconomic costs, but above all in their quality of life. With the present study, the investigators aim to analyze in a combined way different clinical, biological and neuroimaging variables, which allow the clinical staff to anticipate the response to treatment with anti-CGRP monoclonal antibodies in patients with migraine.
연구 개요
상세 설명
The study consists of an initial visit coinciding with the start of treatment, a subsequent visit after 6 months of treatment and finally another after 12 months, coinciding with the end of treatment. In case of worsening after suspension, a clinical visit will be carried out at the time of worsening to evaluate the reintroduction of the drug and in case of reintroduction, a visit will be carried out after 3 months. If patients do not worsen, a visit will be made 6 months after completing treatment.
At each visit, demographic and clinical variables will be collected. In addition, 3 blood tests will be performed corresponding to the beginning of treatment, after 6 months and a month and a half from the last infiltration. Likewise, a brain MRI will be obtained prior to the start of treatment. These blood samples and neuroimaging data will be processed for subsequent analysis.
연구 유형
등록 (실제)
연락처 및 위치
연구 장소
-
-
Aragon
-
Zaragoza, Aragon, 스페인, 50009
- Hospital Clínico Universitario Lozano Blesa
-
-
Basque Country
-
Donostia / San Sebastian, Basque Country, 스페인, 20014
- Hospital Universitario Donostia
-
-
Cantabria
-
Santander, Cantabria, 스페인, 39008
- Hospital Universitario Marqués de Valdecilla
-
-
Castille and León
-
Valladolid, Castille and León, 스페인, 47010
- Hospital Clínico Universitario de Valladolid
-
-
Catalonia
-
Barcelona, Catalonia, 스페인, 08035
- Hospital Universitari Vall d'Hebron Research Institute
-
-
Madrid
-
Madrid, Madrid, 스페인, 28006
- Hospital Universitario de La Princesa
-
-
Valencia
-
Valencia, Valencia, 스페인, 46026
- Hospital Universitario Politécnico La Fe
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
Patients aged between 18 and 65 years with a diagnosis of episodic or chronic migraine who, at the discretion of their neurologist and according to clinical practice guidelines and standard of care, receive treatment with monoclonal antibodies against CGRP (Galcanezumab, Fremanezumab, Eptinezumab) or its receptor (Erenumab) be included. These patients will come from 7 Headache Units in Spain belonging to the following hospitals:
- La Princesa University Hospital
- Vall d'Hebron University Hospital
- Marqués de Valdecilla University Hospital
- Valladolid University Clinical Hospital
- Donostia University Hospital
- Lozano Blesa University Clinical Hospital
- La Fe Polytechnic University Hospital
설명
Inclusion Criteria:
- Patients aged between 18 and 65 years.
- Caucasian ethnicity.
- Patients diagnosed with migraine with and without high-frequency episodic aura (more than 8 days of migraine per month) or chronic by a neurologist expert in headaches and according to the criteria proposed in the International Classification of Headache Diseases, 3rd edition (ICHD- 3).
- Have at least one year of history of migraine.
- Patients must maintain stable preventive treatment in the previous month and not have received botulinum toxin in the month prior to starting the monoclonal antibody.
- Patients able to describe their clinical situation and the characteristics of their headache.
- Grant your informed consent.
Exclusion Criteria:
- Patients who present with another type of non-migraine headache, with the exception of headache due to excessive use of analgesic medication.
- Neurological focus in the examination.
- Pregnancy or breastfeeding period.
- Patients with cognitive deficiency or pathology that may prevent or hinder the correct completion of the study.
- Patients who require changes in preventive treatment during the first 6 months after starting treatment with monoclonal antibodies.
- Patients who present any significant adverse effect that requires withdrawal or change of anti-CGRP drug.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 관찰 모델: COHORT
- 시간 관점: PROSPECTIVE
코호트 및 개입
그룹/코호트 |
개입 / 치료 |
|---|---|
|
Patients with migraine under treatment with monoclonal antibodies against CGRP
Patients with diagnosis of episodic or chronic migraine who, under the criteria of their neurologist and according to the clinical practice guidelines and standard of care, receive treatment with monoclonal antibodies against CGRP (Galcanezumab, Fremanezumab, Eptinezumab) or else its receptor (Erenumab) will be included. |
The patient will keep a record of the presence/absence of headache, average intensity, and need for acute medication. Each patient performs different scales that measure the impact of the migraine on their daily life as well as the disability it may be causing. In turn, each patient performs different scales that measure associated comorbidities such as depression, anxiety or insomnia. Erenumab, Galcenazumeb, Fremanezumab, Eptinezumab |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Biomarkers of positive initial response to monoclonal antibodies
기간: From the beginning of treatment, which is the initial visit, to 18 months of follow-up
|
Establish clinical, demographic, transcriptomic, genetic, molecular and/or radiological characteristics that allow predicting a positive initial response to monoclonal antibodies (biomarkers of therapeutic response). |
From the beginning of treatment, which is the initial visit, to 18 months of follow-up
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Sustained response factors
기간: From the beginning of treatment, which is the initial visit, to 18 months of follow-up
|
To analyze sustained response factors at the sociodemographic, clinical, transcriptomic, genetic, molecular and/or radiological level after the suspension of anti-CGRP drugs. |
From the beginning of treatment, which is the initial visit, to 18 months of follow-up
|
|
Sustained response after discontinuation of the anti-CGRP antibody
기간: From the beginning of treatment, which is the initial visit, to 18 months of follow-up
|
To quantify the proportion of patients who present a sustained response after discontinuation of the anti-CGRP antibody. |
From the beginning of treatment, which is the initial visit, to 18 months of follow-up
|
|
Non-maintained pharmacological response relation with biomarkers
기간: From the beginning of treatment, which is the initial visit, to 18 months of follow-up
|
To characterize whether the non-maintained pharmacological response is related to the variables previously characterized as predictors of chronicity. |
From the beginning of treatment, which is the initial visit, to 18 months of follow-up
|
|
Time until relapse after discontinuation of the anti-CGRP antibody
기간: From the beginning of treatment, which is the initial visit, to 18 months of follow-up
|
To determine the time until relapse after discontinuation of the anti-CGRP monoclonal antibody in those patients who, having presented a positive initial response, discontinue it. |
From the beginning of treatment, which is the initial visit, to 18 months of follow-up
|
|
Biomarkers of patients with high-frequency episodic migraine and chronic migraine
기간: From the beginning of treatment, which is the initial visit, to 18 months of follow-up
|
To validate possible transcriptomic, genetic, molecular and/or radiological characteristics that allow differentiation between patients with high-frequency episodic migraine and chronic migraine in a national multicenter cohort. |
From the beginning of treatment, which is the initial visit, to 18 months of follow-up
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Ana Beatriz Gago Veiga, Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
추가 관련 MeSH 약관
기타 연구 ID 번호
- PI 23- 3054
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
Individual participant data (IPD) will not be shared with other researchers. This decision is based on data protection and confidentiality requirements in accordance with applicable European and national regulations (including GDPR). Given that this is a multicentre observational study conducted in routine clinical practice, access to IPD is restricted to the study investigators for the purposes of the predefined analyses.
Any potential secondary use of the dataset would only be considered in fully anonymized form and subject to prior ethical approval and compliance with applicable data protection legislation.
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .